Vera Therapeutics: JPMorgan considers drug in IgA nephropathy potentially strategically attractive - Analyst sees 140% upside potential

Vera Therapeutics (VERA) positions itself as a late-stage biotechnology company focused on the development and commercialization of transformative treatments for severe immunological diseases. At the core of the company's strategy is the leading clinical candidate Atacicept, a recombinant fusion protein targeting the cytokines BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). These cytokines play a key role in promoting B-cell survival and the production of autoantibodies, which are associated with diseases like IgA nephropathy...